Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual vs Triple Therapy in AF Patients Undergoing PCI (MUSICA-2)
NCT01141153Phase 4Unknown
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Jun 2010
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of acenocoumarol in Atrial fibrillation (AFib) and coronary artery disease (CAD) (2 arms), sponsored by Vall d'Hebron Research Institute. Primary endpoint: Composite of stroke, myocardial infarction, systemic thromboembolism, stent thrombosis and death at 12 months. Status: unknown.
02
Drugs
acenocoumarol
03
Conditions
Atrial fibrillation (AFib)coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT01141153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01141153.